Clinical Trials

Biomarker development for predicting immune checkpoint therapy efficacy of hepatocellular carcinoma (CTMS# 22-0050)

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Sukeshi Patel Arora, MD

For more information about this study
View Details

About This Study

We propose to test whether H1 and H2 clustering can distinguish patients responsive or resistant to the combination therapy with immunotherapy in a prospective clinical study.

What is the criteria to participate?

Note: This is only a partial list of eligibility criteria.

Inclusion Criteria:
Inclusion criteria

1. Patients with HCC who are not candidates for curative or locoregional treatments .

2. Patients who are candidates to receive first-line immunotherapy-based regimens (i.e., atezolizumab/bevacizumab)

3. ECOG performance status 0-2

4. Patients who will have baseline biopsy for HCC and background liver biopsy per SOC

Exclusion Criteria:
Exclusion Criteria

1. Prior systemic therapy for HCC

2. Any contraindication to immunotherapy

a) Prior transplant

b) Uncontrolled autoimmune diseases (i.e., autoimmune hepatitis)

3. Prior anti-PD-L1, anti-PD1, or anti-CTLA4 antibody (or another checkpoint inhibitor)